Prophylactic human papillomavirus vaccines: potential for sea change

References

• deVilliers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology324, 17–27 (2004).
   PubMedGoogle Scholar
• Will C, Schewe C, Petersen I. Incidence of HPV in primary and metastatic squamous cell carcinomas of the aerodigestive tract: implications for the establishment of clonal relationships. Histopathology48, 605–606 (2006).
   PubMedGoogle Scholar
• Clifford GM, Gallus S, Herrero R et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV Prevalence surveys: a pooled analysis. Lancet366(9490), 991–998 (2005).
   PubMed Web of Science ®Google Scholar
• Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates. Perspect. Sex. Reprod. Health36, 6–10 (2004).
   PubMed Web of Science ®Google Scholar
• Burchell AN, Richardson H, Mahmud SM et al. Modeling the sexual transmissibility of HPV infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am. J. Epidemiol.163(6), 534–543 (2006).
   PubMed Web of Science ®Google Scholar
• Frazer I, Cox T, Mayeaux EJ et al. Human papillomavirus infection. Pediatr. Infect. Dis. J.25(1), S65–S81 (2006).
   PubMed Web of Science ®Google Scholar
• Spence AR, Franco EL, Ferenczy A. The role of human papillomaviruses in cancer. Am. J. Cancer4, 49–64 (2005).
   Google Scholar
• Kjaer SK, Munk C, Tran TN et al. The burden of genital warts: a study of nearly 70,000 women from four Nordic countries. Proceedings of the 6th International Multidisciplinary Congress of the European Research Organization on Genital Infection and Neoplasia. Paris, France, SS21–SS04 (2006).
   Google Scholar
• Arduino JM, Roberts C, Skjeldestad FE et al. Cumulative incidence of genital warts by baseline HPV infection status in young, sexually active Norwegian women. Proceedings of the 6th International Multidisciplinary Congress of the European Research Organization on Genital Infection and Neoplasia. Paris, France, SS20–01 (2006).
   Google Scholar
• Dziura B, Quinn S, Richard K. Performance of an imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the uterine cervix. Acta Cytol.50, 309–311 (2006).
   PubMedGoogle Scholar
• Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VAIN). Am. J. Surg. Pathol.30, 1513–1518 (2006).
   PubMed Web of Science ®Google Scholar
• Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope114(Suppl. 104), 1–23 (2004).
   PubMed Web of Science ®Google Scholar
• Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982–1997. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.91(6), 622–635 (2001).
   PubMed Web of Science ®Google Scholar
• Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer118, 3030–3044 (2006).
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol.20(2), 207–225 (2005).
   PubMedGoogle Scholar
• Berry JM, Palefsky JM. A review of human papillomavirus vaccines: from basic science to clinical trials. Front. Biosci.8, S333–S345 (2003).
   Google Scholar
• Pascual A, Pariente M, Godinez JM et al. High prevalence of human papillomavirus 16 in penile carcinoma. Histol. Histopathol.22, 177–183 (2007).
   PubMedGoogle Scholar
• Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. J. Am. Med. Assoc.290, 781–789 (2003).
   PubMed Web of Science ®Google Scholar
• Stanley M. Prophylactic HPV vaccines. J. Clin. Pathol. DOI:10.1136/jcp.2006.040568 (2007) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Brisson M, van de Velde N, Boily MC et al. The health and economic burden of HPV infection, genital warts, cervical dysplasia and cervical cancer in Canada. Presented at the 23rd International Papillomavirus Conference and Clinical Workshop, Prague, Czech Republic (2006).
   Google Scholar
• Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat. Rev. Cancer6(10), 753–763 (2006).
   PubMed Web of Science ®Google Scholar
• Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine23, 2388–2394 (2005).
   PubMed Web of Science ®Google Scholar
• Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am. J. Obstet. Gynecol.191, 114–120 (2004).
   PubMed Web of Science ®Google Scholar
• Winer RL, Hughes JP, Qinghua F et al. Condom use and the risk of genital human papillomavirus infection in young women. N. Engl. J. Med.354(25), 2645–2654 (2006).
   PubMed Web of Science ®Google Scholar
• Drain PK, Holmes KK, Hughes JP, Koutsky LA. Determinants of cervical cancer rates in developing countries. Int. J. Cancer100(2), 199–205 (2002).
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med.347(21), 1645–1651 (2002).
   PubMed Web of Science ®Google Scholar
• Mao C, Koutsky LA, Ault KA et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol.107, 18–27 (2006).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet364(9447), 1757–1765 (2004).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM et al, for the HPV Vaccine Study Group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet367, 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RLR, Petta CA et al. Prophylactic, quadrivalent, human papillomavirus (types 6, 11, 16, 19) L1 virus-like particle vaccine in young women: a randomized, double-blind, placebo-controlled, multicentre, Phase II efficacy trial. Lancet Oncol.6(5), 271–278 (2005).
   PubMed Web of Science ®Google Scholar
• Bryan FJ, Esser MT, Sings HL, Saah AJ, Barr E. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer95(11), 1459–1466 (2006).
   PubMedGoogle Scholar
• Paavonen J; FUTURE II Study Group. Efficacy of a quadrivalent HPV (types 6/11/16/18) L1 virus-like particle (VLP) vaccine against vaginal and vulvar precancerous lesions: a combined analysis. J. Clin. Oncol.24(18S), 5011 (2006).
   Google Scholar
• Siddiqui MAA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil®). Drugs66(9), 1263–1271 (2006).
   PubMed Web of Science ®Google Scholar
• Yu J, Lupinacci L, Railkar R et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine24, 5571–5583 (2006).
   PubMedGoogle Scholar
• Reisinger KS, Block SL, Lazcano-Ponce E et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents. Pediatr. Infect. Dis.26, 201–209 (2007).
   Google Scholar
• McMahon B, Bruden D, Petersen K et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann. Intern. Med.142(5), 333–341 (2005).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Quadrivalent human papillomavirus vaccine. MMWR Recommendations and Reports 56/RR-2, March 23, (2007).
   Google Scholar
• Friedman LS, Kahn J, Middleman AB, Rosenthal SL, Zimet GD. Human papillomavirus (HPV) vaccine: a position statement of the Society for Adolescent Health. J. Adolescent Health39, 620 (2006).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Youth risk behavior survey – United States 2003. MMWR53(S S02), 1–96 (2004).
   PubMedGoogle Scholar
• Expert Committee on Biological Standardization, World Health Organization. Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. Geneva, Switzerland (2006).
   Google Scholar
• Garnett PG. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J. Infect. Dis.191(Suppl. 1), S97–S106 (2005).
   PubMed Web of Science ®Google Scholar
• French KM, Barnabas RV, Lehtinen M et al. Strategies for the introduction of human papillomavirus vaccination: modeling the optimum age- and sex-specific pattern of vaccination in Finland. Br. J. Cancer96, 514–518 (2007).
   PubMed Web of Science ®Google Scholar
• Bleeker MCG, Snijders PFJ, Voorhorst FJ, Meijer CJLM. Flat penile lesions: the infectious “invisible” link in the transmission of human papillomavirus. Int. J. Cancer119, 2505–2512 (2006).
   PubMedGoogle Scholar
• Schiller JT, Lowy DR. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res.66(21), 10229–10232 (2006).
   PubMed Web of Science ®Google Scholar
• Fraser C, Tomassini JE, Xi L et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine25(21), 4324–4333 (2007).
   PubMed Web of Science ®Google Scholar
• Herrero R, Castle PE, Schiffman M et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J. Infect. Dis.191(11), 1787–1789 (2005).
   PubMedGoogle Scholar
• Villa LL, Ault KA, Giuliano AR et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine24, 5571–5583 (2006).
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine24(33–34), 5937–5949 (2006).
   PubMed Web of Science ®Google Scholar
• Kahn J. Vaccination as a prevention strategy for human papillomavirus-related diseases. Adolescent Health37, S10–S16 (2005).
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer111(2), 278–285 (2004).
   PubMed Web of Science ®Google Scholar
• Mendez F, Munoz N, Posso H et al. Cervical co-infection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J. Infect. Dis.192, 1158–1165 (2005).
   PubMedGoogle Scholar
• Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J. Lower Genital Tract Dis.8(3), 188–194 (2004).
   PubMedGoogle Scholar
• Zimet GD, Perkins SM, Sturm LA, Bair RM, Juliar BE. Predictors of STI vaccine acceptability among parents and their adolescent children. J. Adolesc. Health37(3), 179–186 (2005).
   PubMed Web of Science ®Google Scholar
• Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J. Adolesc. Health37(3), 248–251 (2005).
   PubMed Web of Science ®Google Scholar
• Stratton KR, Durch JS, Lawrence RS (Eds). Vaccines for the 21st Century: a tool for decision-making. Natl Acad. Press, DC, USA (2001).
   Google Scholar
• Li M, Cripe TP, Estes PA, Lyon MK, Rose RC, Garcea RL. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J. Virol. Med.71, 2988–2995 (1977).
   Google Scholar
• Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine24(Suppl. 3), S171–S177 (2006).
   PubMedGoogle Scholar
• Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int. J. Cancer106(6), 896–904 (2003).
   PubMed Web of Science ®Google Scholar
• Kohli M, Ferko N, Martin A et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br. J. Cancer96(1), 143–150 (2007).
   PubMed Web of Science ®Google Scholar
• Collins Y, Einstein MH, Gostout BS; Society of Gynecologic Oncologists Education Resource Panel writing group. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynaecologic oncologists. Gynecol. Oncol.102, 552–562 (2006).
   PubMed Web of Science ®Google Scholar
• Saslow D, Runowicz CD, Solomon D et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin.52, 342–362 (2002).
   PubMed Web of Science ®Google Scholar
• Davey E, Barrett A, Irwig L et al. Effect of study design and quality on unsatisfactory rates, cytology classifications and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet367(9505), 122–132 (2006).
   PubMed Web of Science ®Google Scholar
• Wright TC Jr. HPV DNA testing for cervical cancer screening. Int. J. Gynecol. Obstet.95(Suppl. 1), S239–S246 (2006).
   Google Scholar
• American College of Obstetrics and Gynecology Committee on Adolescent Health Care. Evaluation and management of abnormal cervical cytology and histology in the adolescent. Obstet. Gynecol.107(4), 963–968 (2006).
   PubMedGoogle Scholar
• Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine24(Suppl. 3), S42–S51 (2006).
   Web of Science ®Google Scholar
• Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA291(17), 2100–2106 (2004).
   PubMed Web of Science ®Google Scholar
• Ferenczy A. Human papillomavirus infections: current concepts, new developments. J. SOGC19, 369–381 (1997).
   Google Scholar
• Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer119(5), 1095–1101 (2006).
   PubMed Web of Science ®Google Scholar
• Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl Cancer Inst.97, 1072–1079 (2005).
   PubMed Web of Science ®Google Scholar
• Castle PE, Solomon D, Schiffman M, Wheeler CM; ALTS Group. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl. Cancer Inst.97, 1066–1071 (2005).
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med.348(6), 518–527 (2003).
   PubMed Web of Science ®Google Scholar